Rapid DNA methylation-based classification of pediatric brain tumours from

- 2 ultrasonic aspirate specimens
- Michèle Simon^{1*}, Luis P. Kuschel^{2*}, Katja von Hoff³, Dongsheng Yuan², Pablo 4
- Hernáiz Driever¹, Elisabeth G. Hain⁴, Arend Koch⁴, David Capper^{4,5}, Matthias Schulz⁶, 5
- 6 Ulrich-Wilhelm Thomale^{6*}, Philipp Euskirchen^{2,4,5*}
- 8 1 Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin
- 9 and Humboldt Universität zu Berlin, Department of Pediatric Oncology and
- 10 Hematology, Berlin, Germany
- 11 2 Charité-Universitätsmedizin Berlin, Department of Neurology, Berlin, Germany
- 12 3 Department of Paediatric and Adolescent Medicine, Aarhus University Hospital,
- 13 Aarhus, Denmark
- 14 Charité-Universitätsmedizin Berlin, Department of Neuropathology, Berlin,
- 15 Germany

1

3

7

- 16 5 German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer
- 17 Research Center (DKFZ), Heidelberg, Germany
- 18 6 Charité-Universitätsmedizin Berlin, Department of Pediatric Neurosurgery, Berlin,
- 19 Germany

21

30

31

- 20 *authors contributed equally
- 22 Corresponding Author:
- 23 Philipp Euskirchen, MD
- 24 Department of Neuropathology
- Charité Universitätsmedizin Berlin 25
- 26 Charitéplatz 1
- 27 10117 Berlin
- 28 Germany
- 29 E-Mail: philipp.euskirchen@dkfz.de
- 32 Keywords:
- 33 nanopore sequencing, pediatric brain cancer, ultrasonic aspirator NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

34 35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Background: Although cavitating ultrasonic aspirators are commonly used in neurosurgical procedures, the suitability of ultrasonic aspirator-derived tumor material for diagnostic procedures is still controversial. Here, we explore the feasibility of using ultrasonic aspirator-resected tumor tissue to classify otherwise discarded sample material by fast DNA methylation-based analysis using low pass nanopore whole genome sequencing. Methods: ultrasonic aspirator-derived specimens from pediatric patients undergoing brain tumour resection were subjected to low-pass nanopore whole genome sequencing. DNA methylation-based classification using a neural network classifier and copy number variation analysis were performed. Tumor purity was estimated from copy number profiles. Results were compared to microarray (EPIC)-based routine neuropathological histomorphological and molecular evaluation. Results: 18 samples with confirmed neuropathological diagnosis were evaluated. All samples were successfully sequenced and passed quality control for further analysis. DNA and sequencing characteristics from ultrasonic aspirator-derived specimens were comparable to routinely processed tumor tissue. Classification of both methods was concordant regarding methylation class in 16/18 (89%) cases. Application of a platform-specific threshold for nanopore-based classification ensured a specificity of 100%, whereas sensitivity was 78%. Copy number variation profiles were generated for all cases and matched EPIC results in 16/18 (89%) samples, even allowing the identification of diagnostically or therapeutically relevant genomic alterations. Conclusion: Methylation-based classification of pediatric CNS tumors based on ultrasonic aspirator-reduced and otherwise discarded tissue is feasible using timeand cost-efficient nanopore sequencing.

Introduction

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Ultrasonic aspirator devices are frequently used in pediatric neurosurgery for efficient microsurgical resection of brain tumours while minimizing tissue damage to surrounding healthy brain (1). With ultrasonic aspirator, tumor tissue is fragmented in situ by ultrasound-induced vibration and tissue debris is aspirated using suction. To date, ultrasonic aspirator tissue specimens have not been used for routine neuropathological examinations. At the same time, molecular profiling is increasingly used and required in addition to histomorphology for diagnostic workup and comprehensive characterization of pediatric brain tumours (2). In particular molecular classification based on DNA methylation signatures has proven to be a powerful and elegant unbiased approach to identifying tumor type (3) and has been adopted in the current World Health Organization (WHO) classification of central nervous system (CNS) tumours (4). For DNA extraction, however, additional tissue is needed which may be scarce in pediatric neurosurgery. While for histological examination it appears necessary to preserve the integrity of the tissue, DNA methylation profiling (as any nucleic acid-based method) only relies on the integrity of tumor DNA. Repurposing ultrasonic aspirator tissue specimens as a source of tumor DNA for molecular diagnostics would maximize use of tumor tissue. To date, only detection of focal amplifications (5) and gene expression profiling by RNA sequencing (6) in ultrasonic aspirator tissue samples have been explored. The growth patterns of pediatric brain tumors differ from those of adult tumors in that they are more likely to spread in the neuraxis (7). Furthermore, highly aggressive rare embryonal and sarcomatous pediatric CNS tumors for which there are limited therapeutic recommendations and for which immediate initiation of therapy is essential have only recently been molecularly redefined (8). The overall time to integrated diagnosis in pediatric oncology is therefore of considerable importance, and any delay in initiating first-line therapy may be critical. Indeed, the presence of molecular markers defining risk groups in therapy trials also leads to different therapeutic approaches. Recently, we have demonstrated, that low-pass nanopore whole genome sequencing

(WGS) is non-inferior to microarray-based DNA methylation profiling of CNS tumors

(9). In addition, real-time analysis is feasible, enabling a reliable intraoperative

The made available and a de bi no me material necho.

diagnosis within a surgically relevant time frame at low cost (10). In addition, adaptive sequencing allows to enrich genomic regions of interest in the same WGS run to detect clinically relevant SNV and SV (11).

In the present study, we studied whether DNA methylation-based classification can be reliably performed using DNA from tumor tissue fragments obtained by ultrasonic aspirator devices using low-pass nanopore whole genome sequencing in order to overcome time-consuming tissue processing and maximize use of limited material in pediatric neuro-oncology.

Methods

96

97

98

99

100

101

102

103

104105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

Study design

We conducted a prospective, proof-of-concept single-center study using ultrasonic aspirator tissue specimens for molecular characterization of pediatric CNS tumors using nanopore WGS (Fig. 1 (A)). All patients < 18 years who underwent surgery for tumor resection using an ultrasonic aspiration device at the Department of Pediatric Neurosurgery, Charité-Universitätsmedizin Berlin, Germany, between February 6th, 2020, and October 5th, 2020, were screened. Informed written consent was obtained from patients and/or guardians. The study was approved by the local ethics committee (Charité –Universitätsmedizin Berlin, Berlin, Germany; EA2/041/18) and performed according to the guidelines for Good Scientific Practice. Ultrasonic aspirator tissue samples taken with the LEVICS device (Söring, Quickborn, Germany), which are normally discarded after surgery, are collected using a bronchoalveolar lavage trap, which is connected to the suction tubing coming from the sonotrode instruments and connected to the suction reservoir. Thereby about 5ml of fluid including fragmented tumor tissue could be collected. In parallel, regularly resected umor tissue was processed for routine neuropathological procedures including phenotypic-genotypic diagnostics. All study data were archived under an ID key accessible only to the research group (pseudonymization). Pseudonymized study data were recorded using REDCap (13), which was provided by the Berlin Institute of Health's Clinical Research Unit in a certified computing environment.

Ultrasonic aspirator tissue sample processing

Fresh ultrasonic aspiration fluid aliquots were centrifuged at 1.000 rpm for 5 min, supernatant was discarded and pellets stored at -40°C. DNA was extracted from ~25 mg thawed aspirate and purified using the DNeasy Blood & Tissue Kit (Qiagen, NL). Based on the 260/280 ratio (NanoDrop, Thermo Fisher, USA), DNA quality was determined, followed by DNA quantification with a Qubit 4.0 fluorometer using a dsDNA BR Assay (Thermo Fisher, USA).

Nanopore low-pass whole genome sequencing

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

All samples were subjected to low-pass whole genome sequencing as described previously (9). Preprocessing of raw data for sequencing was performed using the publicly available nanoDx pipeline (https://gitlab.com/pesk/nanoDx, v0.5.1). Briefly, basecalling of nanopore FAST5 raw data was performed using guppy v5.0.16 (Oxford Nanopore Technologies, UK) and aligned to the hg19 human reference genome using minimap2 v2.15 (14). In order to assess the feasibility of ultrasonic aspirator-derived nanopore sequencing, the aligned sequencing data was normalized to a six hour sequencing window and were compared to a previously published dataset of 16 brain tumor samples obtained during routine nanopore sequencing from fresh-frozen tumor tissue (9). DNA methylation was assessed using nanopolish v0.11.1 (15). After binarization of beta values with threshold = 0.6 (9), features with zero variance were filtered out, leading to 366,263 CpG sites retained. These were used to train the neural network model with randomly masked features. PyTorch, an open source deep-learning framework, was used to develop the model (16). To obtain class probability estimates that can be used to guide diagnostic decisionmaking, a normalization function and a Softmax layer was used to convert the raw values into a probability that measures the confidence in the brain tumor class assignment (the calibrated score). Returned majority votes were combined to methylation class families (MCF), if feasible (9). Complementarily, data was displayed using t-distributed Stochastic Neighborhood Embedding (t-SNE) (17).

CNS tumor classification

All cases were classified according to the 2016 WHO CNS classification during routine neuropathological examination at the Department of Neuropathology, Charité Universitätsmedizin Berlin. The recent 2021 edition (4) was not yet available during the study period of this patient cohort. Nanopore classification results were compared

to the reference diagnosis as well as microarray-based classification results of the same tumor considering the established cut-off values for the probability score.

Copy number analysis

Copy number variation (CNV) analysis from nanopore WGS data was performed using the QDNAseq package v1.8.0 and R/Bioconductor v3.3 as described before (18, 19). To account for region- and technology-specific artifacts, public nanopore WGS data for the NA12878 human reference genome were processed and subtracted from the normalized bin counts of the tumor samples for case reports. To estimate tumor purity in aneuploid tumors, absolute copy number estimation of nanopore- and microarray-based data was performed using the ACE software package (v1.6.0) (20). All estimates were verified manually.

Methylation array processing

Infinium MethylationEPIC BeadChip microarrays (Illumina) were used to obtain genome-wide DNA methylation profiles for tumor samples during routine neuropathological diagnostic examination. Data were generated following the manufacturer's protocol at the Department of Neuropathology, Charité - Universitätsmedizin Berlin, using >250 ng of DNA from FFPE tissues as input material. For classification, IDAT files were uploaded to the public Heidelberg brain tumour classifier available at https://www.molecularneuropathology.org (v.11b4).

Statistical analysis

- 185 Reproducible and easy-to-deploy pipelines were implemented using snakemake
- 186 (v.7.15.2) (21). Data analysis was mainly performed using R (v.4.0.2). Figures were
- 187 designed using ggplot2 (v.3.3.2). Statistical analyses were performed using IBM
- 188 SPSS[®] 29 (Armonk, N.Y., USA)

Data and code availability

The nanoDx analysis pipeline for end-to-end analysis of nanopore WGS data is available at https://gitlab.com/pesk/nanoDx (v.0.5.1). Source code to reproduce all analyses and sequencing data based figures in this work is provided at https://gitlab.com/pesk/nanoCUSA. Raw sequencing data have been deposited at the European Genome-phenome archive (accession no. tbd), while methylation

microarray data and nanopore methylation calls are available from Gene Omnibus Express (accession no. tbd).

Results

196

197

198 199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

Patient characteristics

A total of 21 children undergoing surgery participated in the study. 3/21 (14.9%) of patients were excluded from analysis due to non-diagnostic scores in microarraybased classification (n=2) or final diagnosis of non-neoplastic disease (n=1). Eventually, our cohort comprised 18 tumor aspirates from 18 pediatric patients (Table 1). 33% of patients (n=6) were male. Median age at surgery was 7.5 years (range 1 to 17 years). Twelve patients suffered from a newly diagnosed cerebral lesion, whereas six samples were obtained from a second or further intervention. Five patients had received previous treatment with vincristine/carboplatin according to the European auidelines for low-grade alioma (LGG) (n=4)cyclophosphamide/vincristine/methotrexate/carboplatin/etoposide according to the current treatment recommendation of the German Society of Pediatric Oncology and Hematology (GPOH) for newly diagnosed medulloblastoma, ependymoma, and pineoblastoma (n=1). One patient with LGG was previously treated with vinblastine monotherapy and targeted therapy using a MEK inhibitor. The most frequent diagnosis was pilocytic astrocytoma (50%, n=9).

Sequencing characteristics of tumor DNA from ultrasonic aspirator tissue samples

Low-pass whole genome sequencing performed for at least 6 hours resulted in a mean genome coverage of 0.44X (range 0.01X to 1.5X, Suppl. Table 1). The mean read length ranged between 4,047 and 10,440 base pairs with a mean of 7,377 base pairs and was comparable to reads obtained in an external cohort of sequencing runs of tumor DNA extracted from fresh-frozen tissue (Fig. 1B). The mean number of CpG sites overlapping the reference atlas was 100,852 CpGs (range: 2,275 to 295,872 CpG sites), exceeding the minimum number of 1,000 overlapping CpG sites for meaningful analysis in 18/18 (100%) samples. In two cases, the minimum number of CpG sites was not achieved initially and required an additional sequencing run. On average, after six hours of sequencing 1,054 Mb of aligned base pairs were obtained

(range: 23.76 Mb - 2299.12 Mb), which again was comparable to sequencing runs 230 231 from fresh-frozen tissue (Fig. 1C). Tumor cell content was reliably estimated from 232 copy number alterations in 4/20 (20%) tumors with a mean tumor purity of 0.37 233 (range 0.25 – 0.65) (Fig. 1D). Tumor purity was higher in ultrasonic aspirator tissue 234 samples compared to FFPE tissue for routine workup in 3 out of 4 (75%) cases.

235

237

238

241

244

251

254

257

236 **DNA** methylation-based classification Tumors were classified based on DNA methylation profiles using a neural network model which had been trained using the Heidelberg brain tumour reference cohort 239 with CNS tumor methylation datasets of 2,801 samples and predictions were made 240 with respect to the 91 methylation classes (MC) or methylation class family (MCF), respectively, as defined in the 11b4 version (3). A single nanopore-specific cut-off 242 value was determined by recalibrating the raw values to identify valid predictions. 243 Receiver operating characteristic curve analysis of the maximum calibrated scores was used to determine an optimal cut-off value > 0.2. 245 Classification results were identical to microarray in 16/18 (89%) of cases and 246 compatible with the integrative histopathological reference diagnosis in 16/18 (89%) 247 cases (Figure 2). Application of the optimal calibrated score threshold of >0.2 resulted in 14/18 cases passing the cut-off all of which were correctly classified, 248 249 corresponding to a specificity of 100% and a sensitivity of 78% on both MC and MCF 250 level (Figure 2). At the MC level, in 2/18 (11%) cases, the score was below the optimal threshold but 252 classification was still correct (one YAP-fusion positive ependymoma, one 253 subependymal giant-cell astrocytoma (SEGA)). 2/18 (11%) cases had discordant results with scores that were below the calibrated nanopore-specific threshold: In the 255 first case, pilocytic astrocytoma (PA) subtype was incorrect (classifying the case as 256 midline PA instead of posterior fossa PA) while correctly classifying the sample as PA on MCF level. The other sample was an IDH-mutant astrocytoma classified as control 258 tissue. Here, additional Sanger sequencing revealed no IDH mutation in the 259 ultrasonic aspirator tissue sample, potentially indicating a sampling issue.

260 For comparison, the microarray-based analysis from matched FFPE tissue yielded a 261 diagnostic score in 16/18 (89%) cases. Of note, the two cases with nondiagnostic 262 score included one case of SEGA that also received a low 263 nanopore/ultrasonic aspirator tissue profiling.

Copy number profiling

Copy number profiles obtained from WGS closely resembled matched array-based profiles in 16/18 (88.9 %) cases and enabled the detection of large chromosomal alterations, whereas two nanopore-based CNVs (both pilocytic astrocytomas) were insufficient for interpretation (Suppl. Figure 1). In contrast, low-level focal gains such as tandem duplications resulting in *BRAF* fusion genes in the PA samples were visually identified in 1/9 (11.1 %) cases from nanopore CNV profiles compared with detection in 8/9 (88.8 %) in matched CNV profiles from methylation microarrays (Suppl. Figure 1).

Discussion

Molecular testing is an essential component of state-of-the-art integrated neuropathological diagnostics for most pediatric brain tumor types. Due to the increasing number of pathological examinations required (such as DNA and RNA gene panel sequencing or methylation microarray), tissue is valuable. This proof-of-principle study reports, to our knowledge, the first application of ultrasonic aspirator-derived tumor tissue for molecular classification of pediatric CNS tumors using low-pass nanopore whole genome sequencing. We show that ultrasonic aspirator-derived tumor fragments are a representative source of tumor DNA with tumor cell content sufficient to DNA methylation-based classification and yielding identical classification results.

Tissue characteristics

Although the use of ultrasonically minced tumor tissue for histopathological analysis of brain tumor tissue has been demonstrated in some studies, the suitability is still matter of debate (23-26). In particular, the grading of glial tumors has been reported difficult as histomorphology was only partly recapitulated.

Using read length distribution of mapped nanopore reads as a proxy of DNA fragment length, we find no significant difference in DNA extracted from fresh ultrasonic aspirator tissue aspirates compared to routinely prepared fresh-frozen tissue. Our analysis thus confirms that high molecular weight genomic DNA suitable for nanopore sequencing can be extracted when ultrasonic aspirator-derived tissue is

used. Additionally, similar aligned base yields indicate comparable sequencing performance. Tumor purity estimations for microarray and nanopore indicate a tendency towards higher tumor purity in ultrasonic aspirator tissue samples. However, the estimation depends on the existence of numerical chromosomal alterations. As expected, the majority of cases within a pediatric cohort are pilocytic astrocytomas which lack relevant aneuploidy. Therefore, tumor purity could only be determined in 4 cases. One of the major advantages of using ultrasonic aspirator tissue samples is that multiple areas of the excised tumor are sampled (23). This is particularly important because analyses based on single biopsies may have potential consequences for treatment decisions in spatially and temporally heterogeneous pediatric tumors (27, 28). In contrast, DNA extraction for methylome profiling is usually done after microdissection of a representative area of the tumor sample with an anticipated tumor cell content of ≥70% and therefore reflects only a subset of the entire tumor

Comparison to microarray-based classification

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

331

(3).

It was recently demonstrated, that the application of nanopore technology can be used with comparable reliability for processing of fresh frozen tissue compared to microarray-based analysis of FFPE material (9). Our analysis confirms its suitability when using ultrasonic aspirator-derived tissue. Similar to the observed sensitivity of 88% in a well-defined validation cohort for microarray-based classification (3), our approach reaches an overall accuracy of 89% and a sensitity of 78% for the > 0.2 cut-off while retaining 100% specificity. In contrast, in a real-world cohort enriched for challenging cases a sensitivity as low as 56% was reported for EPIC-based microarray analysis (29).

Especially low-tumor cell content, like in the infiltration zone of diffuse glioma, can be challenging for the performance of DNA methylation-based classification (30) and was likely the cause for the discordantly classified cases (before application of diagnostic cut-offs) in this cohort. Therefore, low tumor cell content poses a challenge to methylation-based classification in general, independent of the processed tissue type or technology platform used for methylome profiling.

330 Copy number profiles can be derived both from nanopore low-pass WGS and methylation microarray datasets. While the resolution of microarray-based CNV plots

is fixed due to the probe set of the chip, resolution of low-pass WGS-based CNV plots correlates with read yield. In our cohort, the quality of nanopore CNV plots was frequently inferior to the matched microarray-based ones. However, next generation flow cells and chemistries for nanopore sequencing devices offer better yields and are likely to resolve these issues.

Conclusion

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

359

360

364

365

DNA methylation-based classification of pediatric CNS tumors from ultrasonic aspirator-fragmented tissue is feasible using nanopore sequencing. A neural network classifier with nanopore-specific diagnostic score thresholds assures high specificity while achieving acceptable sensitivity. Generation of CN profiles is possible and allows for detection of chromosomal changes, but was currently inferior in detection of focal changes (e.g. *BRAF* tandem duplication) compared to microarray approaches. This approach allows maximum exploitation of available tissue for diagnostics. Since advanced molecular techniques have limited benefit for patients in ressource-challenged centers, our time- and cost-efficient approach may be of particular interest.

Acknowledgments

- 351 We thank Aydah Sabah for expert technical assistance. Computation has been
- performed on the HPC for Research cluster of the Berlin Institute of Health. P.E. has
- been a participant in the BIH-Charité Clinical Scientist Program funded by the Charité
- 354 Universitätsmedizin Berlin and BIH.
- 355 Figures were created in part using Servier Medical Art provided by Servier and
- 356 licensed under a Creative Commons Attribution 3.0 unported license. In addition,
- 357 images illustrating nanopore sequencing were reproduced with permission from
- 358 Oxford Nanopore Technologies Plc, United Kingdom.

Conflicts of interest

- 361 PHD is ICI of the Sprinkle study and advisory board member for Alexion. DC declares
- a patent for a method to classify tumors according to DNA methylation signature. All
- 363 other authors declare no conflicts of interest.

References

367 1. Zebian B, Vergani F, Lavrador JP, Mukherjee S, Kitchen WJ, Stagno V, et al.

- 368 Recent technological advances in pediatric brain tumor surgery. CNS Oncol. 369 2017;6(1):71-82.
- 370 2. Sturm D, Capper D, Andreiuolo F, Gessi M, Kolsche C, Reinhardt A, et al.
- 371 Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. 372 Nat Med. 2023;29(4):917-26.
- 373 3. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA
- 374 methylation-based classification of central nervous system tumours. Nature. 375 2018;555(7697):469-74.
- 376 4. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al.
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
- 378 Neuro Oncol. 2021;23(8):1231-51.
- 379 5. Truong LN, Patil S, Martin SS, LeBlanc JF, Nanda A, Nordberg ML, et al.
- 380 Rapid detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors. Diagn Pathol. 2012;7:66.
- 382 6. Alenda C, Rojas E, Valor LM. FFPE samples from cavitational ultrasonic 383 surgical aspirates are suitable for RNA profiling of gliomas. PLoS One.
- 384 2021;16(7):e0255168.

366

- 385 7. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum:
- biology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):58-66.
- 387 8. Gojo J, Kjaersgaard M, Zezschwitz BV, Capper D, Tietze A, Kool M, et al.
- Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions. Eur J Med Genet. 2023;66(1):104660.
- 390 9. Kuschel LP, Hench J, Frank S, Hench IB, Girard E, Blanluet M, et al. Robust
- 391 methylation-based classification of brain tumours using nanopore sequencing.
- 392 Neuropathol Appl Neurobiol. 2022:e12856.
- 393 10. Djirackor L, Halldorsson S, Niehusmann P, Leske H, Capper D, Kuschel LP, et
- 394 al. Intraoperative DNA methylation classification of brain tumors impacts 395 neurosurgical strategy. Neurooncol Adv. 2021;3(1):vdab149.
- 396 11. Patel A, Dogan H, Payne A, Krause E, Sievers P, Schoebe N, et al. Rapid-
- 397 CNS(2): rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a 398 proof-of-concept study. Acta Neuropathol. 2022;143(5):609-12.
- 399 12. Branton D, Deamer DW, Marziali A, Bayley H, Benner SA, Butler T, et al. The
- 400 potential and challenges of nanopore sequencing. Nat Biotechnol. 2008;26(10):1146-401 53.
- 402 13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
- 403 electronic data capture (REDCap)--a metadata-driven methodology and workflow
- 404 process for providing translational research informatics support. J Biomed Inform.
- 405 2009;42(2):377-81.
- 406 14. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics.
- 407 2018;34(18):3094-100.
- 408 15. Simpson JT, Workman RE, Zuzarte PC, David M, Dursi LJ, Timp W. Detecting
- 409 DNA cytosine methylation using nanopore sequencing. Nat Methods.
- 410 2017;14(4):407-10.
- 411 16. Paszke A, Gross S, Massa F, Lerer A, Bradbury J, Chanan G, et al. Pytorch:
- 412 An imperative style, high-performance deep learning library. Advances in neural
- 413 information processing systems. 2019;32.
- 414 17. van der Maaten L; Hinton G. Visualizing data using t-sne. Journal of Machine
- 415 Learning Research, 9(Nov):2579–2605, 2008.

- 416 18. Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau
- 417 M, et al. Same-day genomic and epigenomic diagnosis of brain tumors using real-
- 418 time nanopore sequencing. Acta Neuropathol. 2017;134(5):691-703.
- 419 19. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et
- 420 al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow
- 421 whole-genome sequencing with identification and exclusion of problematic regions in
- 422 the genome assembly. Genome Res. 2014;24(12):2022-32.
- 423 20. Poell JB, Mendeville M, Sie D, Brink A, Brakenhoff RH, Ylstra B. ACE:
- 424 absolute copy number estimation from low-coverage whole-genome sequencing
- 425 data. Bioinformatics. 2019;35(16):2847-9.
- 426 21. Koster J, Rahmann S. Snakemake--a scalable bioinformatics workflow engine.
- 427 Bioinformatics. 2012;28(19):2520-2.
- 428 22. Moudgil-Joshi J, Kaliaperumal C. Letter regarding Louis et al: The 2021 WHO
- 429 Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol.
- 430 2021;23(12):2120-1.
- 431 23. Rao S, Vazhayil V, Nandeesh BN, Beniwal M, Rao K, Yasha TC, et al.
- 432 Diagnostic Utility of CUSA Specimen in Histopathological Evaluation of Tumors of
- 433 Central Nervous System. Neurol India. 2020;68(6):1385-8.
- 434 24. Finley JL, Silverman JF, Dickens MA. Immunocytochemical evaluation of
- central nervous system tumors obtained by the Cavitron ultrasonic surgical aspirator.
- 436 Diagn Cytopathol. 1990;6(5):308-12.
- 437 25. Silverman JF, Jones FD, Unverferth M, Berns L. Cytopathology of neoplasms
- 438 of the central nervous system in specimens obtained by the Cavitron Ultrasonic
- 439 Surgical Aspirator. Acta Cytol. 1989;33(5):576-82.
- 440 26. Richmond IL, Hawksley CA. Evaluation of the histopathology of brain tumor
- 441 tissue obtained by ultrasonic aspiration. Neurosurgery. 1983;13(4):415-9.
- 442 27. Schmelz K, Toedling J, Huska M, Cwikla MC, Kruetzfeldt LM, Proba J, et al.
- 443 Spatial and temporal intratumour heterogeneity has potential consequences for
- 444 single biopsy-based neuroblastoma treatment decisions. Nat Commun.
- 445 2021;12(1):6804.


455

- 446 28. Lazow MA, Hoffman L, Schafer A, Osorio DS, Boue DR, Rush S, et al.
- 447 Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Acta
- 448 Neuropathol Commun. 2020;8(1):182.
- 449 29. Jaunmuktane Z, Capper D, Jones DTW, Schrimpf D, Sill M, Dutt M, et al.
- 450 Methylation array profiling of adult brain tumours: diagnostic outcomes in a large,
- 451 single centre. Acta Neuropathol Commun. 2019;7(1):24.
- 452 30. Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, et al. Practical
- 453 implementation of DNA methylation and copy-number-based CNS tumor diagnostics:
- 454 the Heidelberg experience. Acta Neuropathol. 2018;136(2):181-210.


Figure legends


Figure 1: **(A)** Overview of the study design including workflow using ultrasonic aspirator tissue specimens for nanopore sequencing for DNA methylation-based classification using a neural network classifier and copy number variation analysis, comparison to microarray-based routine neuropathological profiling and assessment of tumor purity by absolute copy number estimation using ACE. Suitability of ultrasonic aspirator-derived tumor tissue (UA) for nanopore sequencing (T-Test and Mann-Whitney *U* with *P* > .05): **(B,C)** Comparison of **(B)** mean read length and **(C)** read yield obtained from standard nanopore protocol using fresh-frozen (FrFr) tumor tissue vs. ultrasonic aspirator-derived sample material indicates similar sequencing performance. **(D)** In silico tumor purity estimation between nanopore ultrasonic aspirator tissue samples and microarray FFPE tissue. **(E,F)** Representative illustration of matched copy number variation profiles obtained from **(E)** ultrasonic aspirator tissue samples and nanopore sequencing and **(F)** FFPE tumor tissue subjected to EPIC microarray (850K). Red marker indicates a low-level gain of the *BRAF* locus suggestive of a *BRAF* gene fusion.


- **Figure 2**: Nanopore classification methylation class call of ultrasonic aspirator-derived tumor material and the corresponding 2016 WHO CNS reference diagnosis results showing a specificity of 100% and sensitivity of 77.7 % for cases above the calibrated threshold of > 0.2.
- Suppl. Figure 1: Comparison of copy number variation profiles obtained from (A) ultrasonic aspirator tissue samples and nanopore sequencing and (B) FFPE tumor tissue subjected to EPIC microarray (850K).
 - **Table 1:** Overview of the patient cohort.





	Reference diagnosis	Nanopore MC	Classification score	Concordance
(A)	Anaplastic Ependymoma (1)	EPN, PF A (1)		
	Atypical central neurocytoma (1)	CN (1)		
	CNS neuroblastoma (1)	CNS NB, FOXR2 (1)		
	Craniopharyngioma (1)	CPH, ADM (1)		
	Ependymoma, RELA fusion-positive (1)	EPN, RELA (1)		
		LGG, PA MID (1)	score > 0.2 (14)	Concordant (14)
	Pilocytic astrocytoma (8)	LGG, PA PF (7)		
	Schwannoma (1)	SCHW (1)		
(B)	Ependymoma (1)	EPN, YAP (1)	score < 0.2 (2)	Concordant (2)
	Subependymal giant cell astrocytoma (1)	LGG, SEGA (1)	33370 1312 (2)	Sonordank (<u>L</u>)
(C)	Diffuse astrocytoma, IDH-mutant (1)	CONTR, HEMI (1)		
	Pilocytic astrocytoma (1)	LGG, PA MID (1)	score < 0.2 (2)	Discordant (2)






























































chr7

chr2

chr1

chr3

chr5

chr4

chr6

chr9

chr8


chr10

chr12


chr18

chr17


chr19 chr20 chr21 chr22





































chr7

chr8

chr9

chr10

chr11

chr12

chr13

chr15

chr16

chr14

chr19 chr20 chr21 chr22

chr18 chr17

chr5


chr4


chr2

chr1


chr3


chr6








(B) Microarray I DX-BLN-065























Patient ID	Sex	CNS WHO 2016	Microarray methylation class	Probability score	Nanopore methylation class family	tSNE methylation class family concordance	Nanopore methylation class	tSNE methylation class concordance
DX- BLN- 025	F	CNS neuroblastoma	CNS neuroblastoma with FOXR2 activation	0,682	CNS neuroblastoma with FOXR2 activation	+	CNS neuroblastoma with FOXR2 activation	+
DX- BLN- 027	F	Schwannoma	schwannoma	0,854	schwannoma	+	schwannoma	+
DX- BLN- 028	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,583	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX- BLN- 029	F	Ependymoma	ependymoma, YAP fusion	0,101	glioblastoma, IDH wildtype	+	ependymoma, YAP fusion	+
DX- BLN- 037	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,539	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX- BLN- 042	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,557	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX- BLN- 043	М	Ependymoma, RELA fusion- positive	ependymoma, RELA fusion	0,428	ependymoma, RELA fusion	+	ependymoma, RELA fusion	+
DX- BLN- 047	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,5	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX-	М	Anaplastic	ependymoma,	0,754	ependymoma,	+	ependymoma,	+

BLN-		Ependymoma	posterior fossa		posterior fossa		posterior fossa	
048			group A		group A		group A	
DX- BLN- 049	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,12	pilocytic astrocytoma	-	low grade glioma, subclass midline pilocytic astrocytoma	-
DX- BLN- 050	F	Atypical central neurocytoma	central neurocytoma	0,721	central neurocytoma	+	central neurocytoma	+
DX- BLN- 054	F	Diffuse astrocytoma, IDH- mutant	IDH glioma, subclass astrocytoma	0,166	pilocytic astrocytoma	-	control tissue, hemispheric cortex	-
DX- BLN- 064	F	Subependymal giant cell astrocytoma	#NV	0,15	low grade glioma, subependymal giant cell astrocytoma	-	low grade glioma, subependymal giant cell astrocytoma	-
DX- BLN- 065	M	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,472	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX- BLN- 071	F	Pilocytic astrocytoma	#NV	0,485	pilocytic astrocytoma	+	low grade glioma, subclass midline pilocytic astrocytoma	+
DX- BLN- 073	М	Craniopharyngioma	craniopharyngioma, adamantinomatous	0,555	craniopharyngioma, adamantinomatous	+	craniopharyngioma, adamantinomatous	+
DX- BLN- 074	M	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,691	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX- BLN-	М	Pilocytic astrocytoma	low grade glioma, subclass posterior	0,405	pilocytic astrocytoma	+	low grade glioma, subclass posterior	+

075	fossa pilocytic		fossa pilocytic	
	astrocytoma		astrocytoma	